British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...
GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.
A UPMC pulmonologist talks about the symptoms, explains who is most at risk for a severe infection, and tells us how ...
October: time for muddy soccer practices, cider pressing and Halloweentown ... And time to roll up your sleeves.
Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...
Starting in September, the UK’s new RSV vaccine program will offer protection across all age groups — find out what this ...
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
It's been more than a year since the Food and Drug Administration approved the first vaccine to treat RSV. Since then, newly ...
GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
The Nunavut government says it will provide immunization against respiratory syncytial virus to all infants in the territory ...